At the end of March, Health~Holland set up a call for COVID-19 related research proposals. In May we announced that in only one month four projects were awarded by the Health~Holland board. One week later, three more projects were awarded. Now, more good news is to follow; four more projects have been awarded and granted PPP Allowance to start their research.
Intravacc, one of the world’s leading translational research and development vaccine institutes and EpiVax, a biotechnology company, announce that they have entered into a collaboration agreement to further progress an novel vaccine against COVID-19, based on Intravacc’s proprietary Outer Membrane Vesicles (OMV) technology platform.
On Monday the 8th of June, key stakeholders from Massachusetts and the Netherlands will come together in a virtual session to discuss about the developments in both life sciences ecosystems in the light of the COVID-19 pandemic outbreak, and how international collaboration, now and in the future, could contribute to solutions.
Mymetics Corporation announced that Stallergenes Greer and Anergis, reported the results of a joint research study evaluating the effects of the second generation Contiguous Overlapping Peptides (COP) allergen immunotherapy in a therapeutic model of birch allergy, with the aim of shortening the AIT administration schemes.
Leiden University Medical Center (LUMC) will start this year with the construction of the largest non-profit stem cell and gene therapy facility in the Netherlands, and one of the largest facilities in Europe. In the ‘NECSTGEN’ facility, the Netherlands Centre for the Clinical advancement of Stem Cell and Gene Therapies, research will be conducted in the field of regenerative medicine.
De bedrijfsnaam Organon keert terug in Nederland. Dat is het resultaat van overleg tussen de MSD-directie in Nederland en de Landelijke Ondernemingsraad die hierover advies moest uitbrengen. Vanuit de ondernemingsraad is er groen licht voor uitvoering en vervolgstappen in Nederland.
Haermonics, een spin-off van Amsterdam UMC, heeft de effectiviteit en veiligheid bewezen van het spoelen van het hartzakje na een openhartoperatie. Een experimentele opstelling zorgde voor significant minder bloedingsgerelateerde complicaties.